Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea…. Sold as Meticortelone, Sterane, Pred Forte, Pred Mild, Econopred and 2 more. Every FDA application for this active ingredient: 7 branded and 12 generic.
As of Nov 15, 2026, FDA lists 19 applications for Prednisolone Acetate (sold as Meticortelone, Sterane, Pred Forte and others), first approved May 22, 1955, with 1 new use approved and 0 published complete response letters.
First approved: May 22, 1955
Applications: 19
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $157M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
PrednisoloneDrugs with revised indications and a new dosage for the treatment of malignant lymphoma and similar diseases (closely-related diseases). · Shionogi & Co., Ltd. · Jun 26, 2015
PredonineDrugs with a new indication for the treatment of multiple myeloma. · Takeda Pharmaceutical Company Limited · Sep 16, 2011
Clinical Trials
364 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Schering
Abbvie
Sandoz
Pfizer
Sun Pharma Canada
Lupin